Ibrutinib/Venetoclax Produces Encouraging Results in Relapsed/ Refractory CLL

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [21] Continued Long Term Responses to Ibrutinib plus Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial
    Hillmen, Peter
    Boucher, Rebecca H.
    Webster, Nichola
    Dalal, Surita
    Brock, Kristian
    Yates, Francesca
    Sankhalpara, Chhaya
    Macdonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Rawstron, Andrew
    Hillmen, Peter
    BLOOD, 2020, 136
  • [22] Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL
    Rogers, Kerry A.
    McLaughlin, Eric
    Wei, Lai
    Bhat, Seema A.
    Crouse, Arianna
    Grever, Michael R.
    Jones, Dan
    Kittai, Adam S.
    Lozanski, Gerard
    Moran, Mollie
    Reid, Mark
    Sass, Ellen J.
    Suresh, Swetha
    Byrd, John C.
    Woyach, Jennifer A.
    BLOOD, 2023, 142
  • [23] A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL
    Crombie, Jennifer L.
    Tyekucheva, Svitlana
    Savell, Alexandra
    Francoeur, Karen
    Choiniere, Mark
    Montegaard, Josie
    Soumerai, Jacob D.
    Arnason, Jon E.
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    BLOOD, 2019, 134
  • [24] A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
    Ujjani, Chaitra
    Wang, Hongkun
    Skarbnik, Alan
    Trivedi, Neel
    Ramzi, Pari
    Khan, Nadia
    Cheson, Bruce D.
    BLOOD ADVANCES, 2018, 2 (07) : 762 - 768
  • [25] The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
    Akpinar, Seval
    Dogu, Mehmet Hilmi
    Celik, Serhat
    Ekinci, Omer
    Hindilerden, Ipek Yonal
    Dal, Mehmet Sinan
    Davulcu, Eren Arslan
    Tekinalp, Atakan
    Hindilerden, Fehmi
    Ozcan, Busra Gokce
    Hacibekiroglu, Tuba
    Erkurt, Mehmet Ali
    Bagci, Metin
    Namdaroglu, Sinem
    Korkmaz, Gulten
    Bilgir, Oktay
    Cagliyan, Gulsum Akgun
    Ozturk, Hacer Berna Afacan
    Serin, Istemi
    Tiryaki, Tarik Onur
    Ozatli, Duzgun
    Korkmaz, Serdal
    Ulas, Turgay
    Eser, Bulent
    Turgut, Burhan
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : 169 - 173
  • [26] A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!
    Merli, Michele
    Passamonti, Francesco
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (12) : 1303 - 1305
  • [27] Pairing obinutuzumab with venetoclax in relapsed CLL
    Rogers, Kerry A.
    Thompson, Philip A.
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 543 - 545
  • [28] Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma
    Zhou, Zhiyuan
    Zhang, Lei
    Wang, Xinhua
    Li, Xin
    Li, Ling
    Fu, Xiaorui
    Zhang, Xudong
    Li, Zhaoming
    Sun, Zhenchang
    Zhang, Mingzhi
    ANNALS OF HEMATOLOGY, 2021, 100 (06) : 1509 - 1516
  • [29] COST-EFFECTIVENESS OF VENETOCLAX AND RITUXIMAB COMBINATION THERAPY VERSUS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) IN COLOMBIA
    Chacon-Acevedo, K. R.
    Gamboa, O.
    Quitian Reyes, D.
    VALUE IN HEALTH, 2020, 23 : S37 - S37
  • [30] Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS PhaseI Clinical Trial
    Le Gouill, Steven
    Morschhauser, Franck
    Bouabdallah, Krimo
    Cartron, Guillaume
    Casasnovas, Rene-Olivier
    Milpied, Noel-Jean
    Gastinne, Thomas
    Davies, Andrew John
    Herbaux, Charles
    Chiron, David
    Callanan, Mary
    Rule, Simon
    BLOOD, 2018, 132
12345